← Human Trials & Peer-Reviewed Studies
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
Plain-language guide to NCT04604704: phase 2 interventional trial of NAD+, 36 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT04604704
- Phase
- phase 2
- Status
- completed
- Start
- 2021-01-28
- Completion (planned or actual)
- 2023-01-23
- Participants
- 36 (actual)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Covid19; Long COVID-19; Post-COVID-19 Syndrome
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this phase 2 trial, researchers set out to test NAD+.
It had 1 arm (groups): Treatment with LDN and NAD+ (experimental).
The registry classes the interventions as dietary supplement and drug.
More on the Plan
Patients with a positive test for SARS-CoV-2 1-4 months before enrollment will be included.
Subjects should have self diagnosed post-COVID19 syndrome and experiencing persistent fatigue since positive test.
Patients will be screened using the fatigue survey and cases with a moderate to severe score will be included.
Patients will receive LDN and NAD+ treatment for 12 weeks.
Who Took Part
The registry lists 36 actual participants took part.
It was open to people of any sex aged from 18 years up to 65 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Adequate cognitive function to be able to give informed consent. Technologically competent to complete web forms and perform video calls with the PI. Positive PCR test (polymerase chain reaction) result for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) 1-4 months before enrollment. A fatigue score above 9 in the Chalder Fatigue scale upon enrollment. Willing to fill out regular questionnaires.
The full record lists 7 inclusion and 9 exclusion criteria; among the exclusions: taking opioid analgesics, or undergoing treatment for opioid addiction; opioid dependence or withdrawal syndrome; known sensitivity to naltrexone.
How the Study Was Run
Design: single-group and open-label.
Being open-label, the NAD+ study did not mask who received what.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2021-01-28 with completion listed for 2023-01-23.
It ran at 1 site in United States.
Its stated primary purpose is treatment.
What This Means in Plain Language
Put simply, this is a phase 2 trial of NAD+ in 36 people.
Its size is small, so on its own it can only give an early look.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the NAD+ compound page, all human trials.
Our Notes on the Compound
NAD+: The coenzyme that accepts electrons at complex I.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.